Michelle G. Goveia

发表

Concomitant Use of an Oral Live Pentavalent Human-Bovine Reassortant Rotavirus Vaccine With Licensed Parenteral Pediatric Vaccines in the United States

Penny M Heaton, Zoe M Rodriguez, Michelle G. Goveia, 2007, The Pediatric infectious disease journal.

Analysis of safety data in children after receiving two doses of ProQuad® (MMRV).

K. Reisinger, S. Klopfer, S. Black, 2014, Vaccine.

Public Health Impact and Cost-Effectiveness of Hepatitis A Vaccination in the United States: A Disease Transmission Dynamic Modeling Approach.

E. Elbasha, C. Acosta, Michelle G. Goveia, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Efficacy of Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine Based on Breastfeeding Frequency

Penny M Heaton, Michelle G. Goveia, M. Dallas, 2008, The Pediatric infectious disease journal.

Association Between State Hepatitis A Vaccination Requirements and Hepatitis A Vaccination Rates.

Michelle G. Goveia, Alexandra Bhatti, C. Carias, 2022, Journal of the Pediatric Infectious Diseases Society.

Burden of rotavirus gastroenteritis and distribution of rotavirus strains in Asia: a systematic review.

K. Kawai, M. O'Brien, Michelle G. Goveia, 2012, Vaccine.

Asthma awareness/evironmental practices in childcare centers

G. Windham, Michelle G. Goveia, R. Kreutzer, 2005 .

Development, clinical evaluation, and post‐licensure impact of RotaTeq, a pentavalent rotavirus vaccine

Michelle G. Goveia, M. Ciarlet, C. Ranucci, 2011, Annals of the New York Academy of Sciences.

Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines

S. Klopfer, C. Acosta, Michelle G. Goveia, 2018, Human vaccines & immunotherapeutics.

Planning for monitoring the introduction and effectiveness of new vaccines using real-word data and geospatial visualization: An example using rotavirus vaccines with potential application to SARS-CoV-2

L. Finelli, E. Dasbach, Michelle G. Goveia, 2021, Vaccine: X.

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

J. Heyse, K. O'Brien, P. van Damme, 2006, The New England journal of medicine.

Postdose 3 G1 serum neutralizing antibody as correlate of protection for pentavalent rotavirus vaccine

G. Liu, Michelle G. Goveia, D. Hille, 2017, Human vaccines & immunotherapeutics.

Analysis by rotavirus gene 6 reverse transcriptase-polymerase chain reaction assay of rotavirus-positive gastroenteritis cases observed during the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST)

T. Vesikari, D. Matson, P. Dennehy, 2014, Human vaccines & immunotherapeutics.

Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalizations and deaths in six Asian countries

L. Markson, Michelle G. Goveia, M. Ciarlet, 2011, Human vaccines.

Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalisations in Brazil.

L. Markson, V. Munford, Michelle G. Goveia, 2011, Memorias do Instituto Oswaldo Cruz.

CHIKUNGUNYA MIMICKING ATYPICAL KAWASAKI DISEASE IN AN INFANT

Michelle G. Goveia, M. Dallas, B. Kuter, 2010, The Pediatric infectious disease journal.

RotaTeq: Progress toward developing world access.

Michelle G. Goveia, Christopher B. Nelson, M. Ciarlet, 2010, The Journal of infectious diseases.

RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.

P. van Damme, T. Vesikari, Penny M Heaton, 2009, Vaccine.

Efficacy, Immunogenicity, and Safety of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine at the End of Shelf Life

T. Vesikari, S. Block, Penny M Heaton, 2007, Pediatrics.

The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Penny M Heaton, P. Dennehy, Michelle G. Goveia, 2007, International Journal of Infectious Diseases.

Impact of Acute Rotavirus Gastroenteritis on Pediatric Outpatient Practices in the United States

S. Coffin, Michelle G. Goveia, J. Stek, 2006, The Pediatric infectious disease journal.

Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis.

P. Offit, Penny M Heaton, Michelle G. Goveia, 2005, The Journal of infectious diseases.

Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis.

Michelle G. Goveia, Benjamin P Chan, P. R. Patel, 2007, Journal of the American Academy of Dermatology.

Heterogeneity of Rotavirus Vaccine Efficacy Among Infants in Developing Countries

G. Liu, Michelle G. Goveia, D. Hille, 2017, The Pediatric infectious disease journal.

Vaccine Coverage for United States Infants at Milestone Ages: Missed Opportunities for Vaccination

Dongmu Zhang, M. O'Brien, Michelle G. Goveia, 2016, Journal of the Pediatric Infectious Diseases Society.

Timing of Monovalent Vaccine Administration in Infants Receiving DTaP-based Combination Vaccines in the United States

David R. Johnson, L. Wolfson, Michelle G. Goveia, 2022, The Pediatric infectious disease journal.

Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.

R. Ward, T. Vesikari, P. Offit, 2006, Vaccine.

Protective immune responses against Haemophilus influenza type B elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS™).

Michelle G. Goveia, J. Stek, M. Wilck, 2021, Vaccine.

Hepatitis B and pertussis antibodies in 4- to 5-year-old children previously vaccinated with different hexavalent vaccines

C. Acosta, T. Vesikari, David R. Johnson, 2019, Human vaccines & immunotherapeutics.

CHILDREN's SUSCEPTIBILITY TO CHEMICALS: A REVIEW BY DEVELOPMENTAL STAGE

John Balbus, Rebecca Parkin, J. Balbus, 2004, Journal of toxicology and environmental health. Part B, Critical reviews.

Correction, Vol. 8, No. 10

Susie Wong, A. Woodward, J. Kruger, 2003, Emerging Infectious Diseases.

1068Vaccine Coverage at Milestone Ages among Infants in the United States, 2009-2012

Dongmu Zhang, M. O'Brien, Michelle G. Goveia, 2014, Open Forum Infectious Diseases.

A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants

V. Kanchan, M. Yunus, W. Khan, 2019, Human vaccines & immunotherapeutics.

Safety and Efficacy of the Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine in Healthy Premature Infants

Penny M Heaton, Zoe M Rodriguez, Michelle G. Goveia, 2007, The Pediatric infectious disease journal.

Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach

E. Dasbach, E. Elbasha, C. Acosta, 2018, BMC Infectious Diseases.

Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA™).

S. Klopfer, Michelle G. Goveia, J. Stek, 2021, Vaccine.

Cost-effectiveness of routine catch-up hepatitis a vaccination in the United States: Dynamic transmission modeling study.

E. Elbasha, Michelle G. Goveia, Yoonyoung Choi, 2021, Vaccine.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen)

T. Vesikari, D. Matson, Penny M Heaton, 2011, Human vaccines.

Analysis of safety data in children after receiving two doses of ProQuad® (MMRV).

K. Reisinger, S. Klopfer, S. Black, 2014, Vaccine.

Burden of Childhood Rotavirus Disease in the Outpatient Setting of the Russian Federation

N. Tikunova, A. Podkolzin, Michelle G. Goveia, 2017, The Pediatric infectious disease journal.